At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SNDX Syndax Pharmaceuticals
Trading 08-31 14:21:02 EDT
19.19
-0.35
-1.79%
High19.46Low19.00Vol390.90K
Open19.44D1 Closing19.54Amplitude2.35%
Mkt Cap1.71BTradable Cap1.54BTotal Shares89.30M
T/O7.51MT/O Rate0.49%Tradable Shares80.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nvidia, Salesforce, Marvell, Veeva, Okta, Hormel, and More Stocks That Explain Today's Market
Dow Jones  ·  08-27
Nvidia, Salesforce, Marvell, Veeva, Okta, Hormel, and More Stocks That Explain Today's Market
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating
MT Newswires Live  ·  08-21
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating
Syndax Pharmaceuticals, Inc. : UBS Cuts Target Price to $33 from $37
THOMSON REUTERS  ·  08-21
Syndax Pharmaceuticals, Inc. : UBS Cuts Target Price to $33 from $37
Syndax price target lowered to $33 from $37 at UBS
TIPRANKS  ·  08-21
Syndax price target lowered to $33 from $37 at UBS
Thursday's Top 20 US Stock Transactions: Micron Rises 3.97% Following $10 Billion Research Lab Announcement
Deep News  ·  08-21
Thursday's Top 20 US Stock Transactions: Micron Rises 3.97% Following $10 Billion Research Lab Announcement
Syndax Pharmaceuticals Earnings Call Signals Strong Momentum
TIPRANKS  ·  08-20
Syndax Pharmaceuticals Earnings Call Signals Strong Momentum
Oracle, Software Stocks Drop as AI Trade Seesaws
Dow Jones  ·  08-17
Oracle, Software Stocks Drop as AI Trade Seesaws
Stronger Demand and Spreading Price Power: Key Signals from Chipmakers' Second-Quarter Reports
Stock News  ·  08-17
Stronger Demand and Spreading Price Power: Key Signals from Chipmakers' Second-Quarter Reports
Top US Stock Movers on August 14: Storage Sector Surge Powered by Micron and SanDisk
Deep News  ·  08-14
Top US Stock Movers on August 14: Storage Sector Surge Powered by Micron and SanDisk
Why great earnings haven't been good enough for AI hardware stocks
Morning Star AU  ·  08-13
Why great earnings haven't been good enough for AI hardware stocks
【US Pre-Market】Apple Downgraded, Berkshire Earnings in Focus; Commercial Space Stocks Rise as RKLB and ASTS Face Earnings Catalysts
TradingKey  ·  08-10
【US Pre-Market】Apple Downgraded, Berkshire Earnings in Focus; Commercial Space Stocks Rise as RKLB and ASTS Face Earnings Catalysts
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
Simply Wall St.  ·  08-09
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
U.S. Stocks Decline Midday Thursday as Traders Monitor Iran Tensions, Sandisk Drops 5%
Deep News  ·  08-07
U.S. Stocks Decline Midday Thursday as Traders Monitor Iran Tensions, Sandisk Drops 5%
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth
Reuters  ·  08-06
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth
Syndax Grants Stock Option Awards for 59,250 Shares to Five New Employees
Reuters  ·  08-06
Syndax Grants Stock Option Awards for 59,250 Shares to Five New Employees
Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook
Reuters  ·  08-06
Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-06
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Reuters  ·  08-05
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Syndax Pharmaceuticals, Inc. : Bofa Global Research Cuts Price Objective to $26 from $29
THOMSON REUTERS  ·  08-05
Syndax Pharmaceuticals, Inc. : Bofa Global Research Cuts Price Objective to $26 from $29
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)
TIPRANKS  ·  08-05
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)

Introduction

Company Name.
Syndax Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Issue price:
--